Anthracycline cardiomyopathy monitored by morphologic changes
about
Doxorubicin cardiomyopathyProtection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expressionChemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative StressOrthotopic Heart Transplantation and Mechanical Circulatory Support in Cancer Survivors: Challenges and OutcomesUnderstanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonanceMito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical modelMyocardial diseases of animalsLong term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling.Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectantsCardiac imaging approaches to evaluate drug-induced myocardial dysfunctionEarly detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography.A mouse model for juvenile doxorubicin-induced cardiac dysfunctionCardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionMolecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up.Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitroAndrogen receptor counteracts Doxorubicin-induced cardiotoxicity in male miceEarly Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-mapping Cardiac Magnetic Resonance Imaging: An Animal Study.Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction.Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.Doxorubicin induces cytotoxicity through upregulation of pERK-dependent ATF3.Cardiovascular toxicities from systemic breast cancer therapy.Anthracycline cardiotoxicity: prevalence, pathogenesis and treatmentCardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerAttenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.Early identification of anthracycline cardiomyopathy: possibilities and implications.Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryAnthracycline treatment and ventricular remodeling in left ventricular assist device patients.Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and Hypertrophy.Endomyocardial biopsy in the evaluation of conditions leading to cardiac transplantation and in the evaluation of cardiac allograft rejection.Adriamycin cardiotoxicity in vivo. Selective alterations in rat cardiac mRNAs.Doxorubicin-induced alterations in cultured myocardial cells stimulate cytolytic T lymphocyte responsesCytolytic T lymphocytes and antibodies to myocytes in adriamycin-treated BALB/c mice. Evidence for immunity to drug-induced antigens.Anthracyclines selectively decrease alpha cardiac actin mRNA abundance in the rat heartUltrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity.Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits.The effect of mitoxantrone treatment in beagle dogs previously treated with minimally cardiotoxic doses of doxorubicin.Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.Adriamycin cardiotoxicity monitoring by radionuclide scan.Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin.
P2860
Q24606920-5FDC200B-4917-4990-ACF3-93F6CD1335AAQ24791372-28BAED83-80F4-4082-B19B-EBDEF1198147Q26780547-893DDA4A-D283-46E0-B53C-0E5FD5FF5AC8Q26785414-6CA32CAF-18CF-40F7-BE35-91C468E4ED5EQ26859193-67CAB842-2DC1-4D15-AD8B-44C6D8A21ECDQ27310238-DB46811F-021B-49C1-8D5F-B3D6E50905B3Q27478460-F94CC623-E1C1-4B96-AC72-4991F2943D19Q28361151-255345FE-2F55-463C-B1B3-BD2D2C723571Q28367065-B0381112-B12C-47E9-A236-086A5F756406Q30446453-8E0D8E3E-31C2-4AEB-8471-8CAC08C68403Q30491590-1F7EA386-992A-40D5-B13D-7923A07E76D9Q33572418-4064BB9F-57F1-46D8-BC9A-694C5148FC51Q33574045-97A10A8D-6FAD-4BA6-AFEE-63A329D222D4Q33578496-752FE61F-4905-4293-B6F2-0A8B8C2E7645Q33614685-C5822BA5-EC96-417E-A083-5B9C225155C2Q33637455-B0313768-125F-4348-9411-B74714FC2908Q33752979-5115CE86-E0FC-46D4-850B-FDF953DE98F3Q34037001-CFB5BCD7-1F61-45CF-8AED-DD2CDA5EC003Q34092826-898BE89C-7184-4FF7-A3D5-EBE90D6040ABQ34128868-3C1A4062-D9E7-4072-9894-AFCB0920BE5EQ34427830-033C23BB-C94D-4176-8263-BA9EF5C420FCQ34630349-EBC88E71-315B-4AA9-BA74-CFCF8546D9C8Q34639876-75AA156F-03D3-4ED6-A887-CB915A24BB13Q34775370-C1ED5D7F-D7DA-4EB9-9BE0-FCF04A23E5C3Q34793299-F53DCE23-0482-4E0F-8E36-C615E014A9B4Q34800157-ADE21386-4E43-45BD-B24D-88475872D15AQ35039202-361CA35B-1B2C-4848-A3EB-4F1A8F3B4186Q35246219-92D97CAF-B734-4ED3-B26A-11D3E4224247Q35391254-66163F8D-D2C2-4148-BB4E-55B4DEB4C490Q35654844-AC7E9330-9611-4410-8CB1-DC6E8E22B2BDQ35811720-F13CCB61-7E48-4251-8A42-8C3B36FE7310Q35811834-92ED390E-14F9-4DA8-A24E-F26C12C28E9AQ35830962-C81D2F91-F101-4E3F-A94D-E428D09BA8C0Q35832113-B6CE2606-1A51-4AA9-9A27-F7F4A2F48767Q35834982-91AC1A49-5902-4667-8FFB-A3F753D79673Q35855914-0F97D6A7-2347-4BB8-8DB5-C3AAF2C2C8AFQ35856510-D8383CC9-D6B0-4C1E-B913-6B82902534C7Q36022217-CA31DA43-38D0-472E-8C64-04409FD14FFCQ36047956-E2A7F47C-4148-4EF3-815B-C18E942799B8Q36148627-5922E8C7-E4C5-4C3E-BB45-D2E6889A57FF
P2860
Anthracycline cardiomyopathy monitored by morphologic changes
description
1978 nî lūn-bûn
@nan
1978 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1978 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
name
Anthracycline cardiomyopathy monitored by morphologic changes
@ast
Anthracycline cardiomyopathy monitored by morphologic changes
@en
Anthracycline cardiomyopathy monitored by morphologic changes
@nl
type
label
Anthracycline cardiomyopathy monitored by morphologic changes
@ast
Anthracycline cardiomyopathy monitored by morphologic changes
@en
Anthracycline cardiomyopathy monitored by morphologic changes
@nl
prefLabel
Anthracycline cardiomyopathy monitored by morphologic changes
@ast
Anthracycline cardiomyopathy monitored by morphologic changes
@en
Anthracycline cardiomyopathy monitored by morphologic changes
@nl
P2093
P3181
P1476
Anthracycline cardiomyopathy monitored by morphologic changes
@en
P2093
J R Daniels
M E Billingham
M R Bristow
P304
P3181
P407
P577
1978-06-01T00:00:00Z